Yuhei Okubo
Japanese Foundation for Cancer Research
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Yuhei Okubo.
European Urology | 2008
Satoru Kawakami; Noboru Numao; Yuhei Okubo; Fumitaka Koga; Shinya Yamamoto; Kazutaka Saito; Yasuhisa Fujii; Junji Yonese; Hitoshi Masuda; Kazunori Kihara; Iwao Fukui
OBJECTIVES Using cohorts examined by extended biopsy, we developed and validated multivariate models predicting prostate cancer on initial biopsy and examined whether these extended biopsy-based models outperform previously established models. METHODS Initial extended biopsy (median 22 cores) was performed in 1509 Japanese men including 1083 at Tokyo Medical and Dental University Hospital (TMDU) and 426 at Cancer Institute Hospital (CIH). Logistic regression-based nomograms 1 and artificial neural network (ANN) 1 incorporating age, digital rectal examination, and prostate-specific antigen (PSA) and free PSA, and nomogram 2 and ANN2 further incorporating transrectal ultrasound (TRUS) findings and prostate volume were constructed on the TMDU data. These and previously established models were externally validated on the CIH data set and predictive accuracy was compared directly. RESULTS Without TRUS-derived information, nomogram 1 outperformed the ANN1. With TRUS-derived information, nomogram 2 was more accurate than ANN2. External validation revealed applicability of the Western models to Japanese population, superiority of the nomograms over ANN models, and better predictive accuracy of our extended biopsy-based nomograms than the previous 6-10-core biopsy-based models. Using nomograms 1 and 2, 16% and 19% unnecessary biopsies would be saved at 95% sensitivity. CONCLUSIONS We developed new nomograms predicting prostate cancer on initial biopsy in men with PSA <20ng/ml. Predictive accuracy of these extended biopsy-based nomograms is better than those of previously established models based on 6-10-core biopsies. Our models might help clinicians to decide if a patient requires biopsy and to avoid unnecessary biopsies.
BJUI | 2009
Toshiki Kijima; Yasuhisa Fujii; Taisuke Suyama; Yuhei Okubo; Shinya Yamamoto; Hitoshi Masuda; Junji Yonese; Iwao Fukui
To investigate the rate of objective response and the skeletal‐related event (SRE)‐free survival after combined therapy with radiotherapy (RT) and zoledronate in patients with bone metastases from renal cell carcinoma (RCC).
Urology | 2009
Yasuhisa Fujii; Shinya Yamamoto; Junji Yonese; Satoru Kawakami; Yuhei Okubo; Taisuke Suyama; Yoshinobu Komai; Toshiki Kijima; Iwao Fukui
OBJECTIVES To present a novel technique to prevent inguinal hernias after radical retropubic prostatectomy (RRP). The incidence of inguinal hernia after RRP has been reported to occur in the range 12%-21%. Indirect hernias are more common than direct hernias after RRP. METHODS A total of 569 Japanese patients with prostate cancer underwent antegrade RRP between January 2001 and February 2007. Since February 2006, 138 patients underwent procedures for concurrent inguinal hernia prevention at the time of RRP. For hernia prevention, the processus vaginalis was ligated close to the peritoneal cavity and transected. The remaining 431 patients who underwent the same RRP procedures without hernia prevention were considered control group. The incidence rates of postoperative inguinal hernia in the 2 groups were statistically compared. RESULTS An inguinal hernia developed postoperatively in 105 (24%) of the 431 control patients during follow-up of median 42 months. Hernia-free survival rates were 87%, 81%, and 77%, for 1-, 2-, and 3-year, respectively. By contrast, 2 of the 138 patients (1.4%) who underwent hernia prevention developed an inguinal hernia during follow-up of median 24 months. Hernia-free survival rates were both 99% for 1- and 2-year (P <.0001). The hernia prevention procedure added approximately 10 minutes to the surgery time. There were no significant complications associated with the hernia prevention procedure. CONCLUSIONS Our results suggest that this prophylactic measure is safe and effective to prevent post-RRP inguinal hernias. However, a longer follow-up period is needed to confirm the results.
BJUI | 2008
Yasuhisa Fujii; Junji Yonese; Satoru Kawakami; Shinya Yamamoto; Yuhei Okubo; Iwao Fukui
To compare the effects of leuprolide acetate and goserelin acetate for suppressing serum testosterone levels in Japanese patients with prostate cancer, as several recent studies suggested that serum testosterone is not always suppressed below the upper limit of the castration range in patients using luteinizing hormone‐releasing hormone (LH‐RH) agonists, especially leuprolide acetate.
BJUI | 2012
Kazutaka Saito; Shinji Urakami; Yoshinobu Komai; Yosuke Yasuda; Yuichi Kubo; Shinichi Kitsukawa; Yuhei Okubo; Shinya Yamamoto; Junji Yonese; Iwao Fukui
Study Type – Prognosis (cohort)
International Journal of Urology | 2008
Manabu Tatokoro; Satoru Kawakami; Junji Yonese; Yasuhisa Fujii; Yuhei Okubo; Shinya Yamamoto; Hideki Takeshita; Yoshinobu Komai; Yuichi Ishikawa; Iwao Fukui
Abstract: We report the effectiveness of a combination chemotherapy consisting of ifosfamide, 5‐fluorouracil, etoposide and cisplatin (IFEP chemotherapy) against metastatic adenocarcinoma of the urachus. From April 1995 to November 2004, four patients with adenocarcinoma of the urachus who developed metastases after definitive surgery were treated with the IFEP chemotherapy followed by consolidative radiotherapy or salvage surgery in good responders. During the median follow‐up period of 26 months, three of the four patients responded to the regimen (75%). In one patient with pulmonary metastases, four cycles of the IFEP chemotherapy, followed by stereotactic consolidative radiotherapy resulted in a complete remission for more than 8 years. Two patients achieved partial remission after the IFEP chemotherapy. We have demonstrated the IFEP chemotherapy is one of the most effective chemotherapy regimens against metastatic adenocarcinoma of the urachus. A multimodal treatment strategy, even with curative intent, can be considered when a sufficient effect was obtained by the IFEP chemotherapy.
International Journal of Urology | 2008
Toshiki Kijima; Yasuhisa Fujii; Taisuke Suyama; Yuhei Okubo; Junji Yonese; Iwao Fukui
Abstract: Bisphosphonates (BP) are inhibitors of bone‐resorption and have become the current standard of care for preventing skeletal complications associated with bone metastases. Although previous reports have also suggested potent antitumor, antiangiogenic and immunomodulatory properties of BP, there is debate about the clinical relevance of experimental in vitro and in vivo findings. We report a renal cell carcinoma case in which multiple lung and bone metastases displayed remarkable remission to BP therapy using 30 mg pamidronate once, 4 mg zoledronate once, and weekly 10 mg incadronate 10 times for 3 months. This is the first case report to demonstrate that BP therapy is effective to non‐osseous visceral metastasis as well as bone metastases in the clinical setting.
International Journal of Urology | 2007
Yuhei Okubo; Junji Yonese; Satoru Kawakami; Sinya Yamamoto; Yoshinobu Komai; Hideki Takeshita; Yuichi Ishikawa; Iwao Fukui
Abstract: Renal cell carcinoma (RCC) causes many kinds of symptoms such as hypercalcemia, hypertension, polycythemia and fever. Here we describe a rare case of RCC presenting with a persistent cough. After radical nephrectomy, the obstinate cough disappeared. When the tumor recurred locally, the cough also recurred. Furthermore, the cough disappeared completely again after the removal of the recurrent tumor. Although all the clinical findings suggested that the RCC caused the cough, we could not identify a specific humoral substance responsible for the cough.
International Journal of Urology | 2010
Shinya Yamamoto; Satoru Kawakami; Junji Yonese; Yasuhisa Fujii; Tetsuro Tsukamoto; Yuhei Okubo; Toshiki Kijima; Yuichi Ishikawa; Iwao Fukui
Objectives: To investigate intraoperative and early postoperative complications of antegrade radical prostatectomy with intended wide resection (aRP) for clinically locally advanced prostate cancer (cLAD) and to compare with those of aRP for clinically localized prostate cancer (cLD).
International Journal of Urology | 2008
Yoshinobu Komai; Yasuhisa Fujii; Yuhei Okubo; Shinya Yamamoto; Satoru Kawakami; Junji Yonese; Iwao Fukui
Objectives: To evaluate the efficacy and toxicity of perioperative combination chemotherapy with ifosfamide, 5‐fluorouracil, etoposide and cisplatin (IFEP) in bladder cancer patients with regional lymph node metastases treated by radical cystectomy.